The South African Stroke Risk in General Practice Study

Myles Connor, Paul Rheeder, Alan Bryer, Megan Meredith, Marlene Beukes, Asher Dubb and Vivian Fritz, on behalf of the Southern African Stroke Foundation

Background. Incidence of stroke is increasing in sub-Saharan Africa and stroke prevention is an essential component of successful stroke management. General practitioners (GPs) are well placed to manage stroke risk factors. To design appropriate strategies for risk factor reduction we need to know the risk factor prevalence in each of the population groups attending GPs. The aim of this study was to establish the prevalence of stroke risk factors in the South African general practice population.

Method. We conducted a multicentre, observational study of patients attending general practice in South Africa. Two hundred general practices were randomly selected from lists provided by pharmaceutical representatives. Each GP approached 50 consecutive patients aged 30 years and older. Patients completed an information sheet and the GP documented the patient's risk factors. The resulting sample is relevant if not necessarily representative in a statistical sense.

Results. A total of 9,731 questionnaires were returned out of a possible 10,000. The mean age of participants was 50.7 years. Seventy-six per cent had 1 or more risk factors and 40% had 2 or more risk factors. Hypertension was the commonest risk factor in all population groups (55%) but was highest in black patients (59%). Dyslipidaemia was commonest in whites (37%) and least common in blacks (5%). Diabetes was commonest in Asians (24%) but least common in whites (8%). Risk factors other than smoking increased with age.

Conclusion. This study provides unique data on the prevalence of stroke risk factors in a South African general practice population. Risk factors are common in all population groups, but differ in distribution among the groups. There is considerable opportunity to reduce the burden of stroke in South Africa through GP screening for and treatment of risk factors.


Stroke is the third commonest cause of death worldwide and over two-thirds of these deaths occur in developing regions such as sub-Saharan Africa. Local South African vital registration figures and a verbal autopsy study from the Agincourt Health and Population Unit, a rural demographic surveillance site in Limpopo province, confirm that stroke is an increasingly important cause of death in South Africa. But most people survive stroke and about half are disabled, placing an enormous burden on the survivors, their families and the community.

The acute management of stroke has improved dramatically over the last decade with the introduction of stroke units, stroke management protocols and national guidelines, and acute treatments such as thrombolysis. However, the most cost-effective approach to management is to prevent the stroke in the first place. To do this we need to reduce the individual patient's stroke risk factors (high-risk strategy), and reduce risk factors throughout the population (mass strategy).

Conventional stroke risk factors are divided into those we cannot influence such as increasing age, male gender, family history, socio-economic status and race; and those we can potentially influence such as hypertension, diabetes mellitus (DM), atrial fibrillation, smoking, hypercholesterolaemia, excessive alcohol intake, obesity, physical inactivity, and prothrombotic factors. One of the most important risk factors for recurrent stroke is prior stroke or transient ischaemic attack (TIA). About 30% of people who have had a stroke or TIA will have another stroke during the following 5 years; and almost half of these will occur within 6 months to a year of the initial event. Appropriate secondary prevention reduces this risk significantly. General practitioners (GPs) play a major role in detecting and treating modifiable risk factors and implementing primary and secondary stroke prevention measures.

It is well established that the relative importance of risk factors for stroke and cardiovascular disease differs between populations. If we are to design locally appropriate strategies to address risk factor reduction within the general practice population to facilitate both the high-risk and practice.
population, then we need to know the prevalence of risk factors in each of the South African population groups. The aim of this study was to establish the prevalence of the most important stroke risk factors in the South African general practice population to facilitate both the high-risk and population approaches to stroke prevention.

Methods

We conducted a multicentre, observational study of patients attending general practice in South Africa.

Participant selection

Seventeen pharmaceutical company representatives countrywide were asked to submit a list of the names of 40 GPs in their respective areas (680 practices in total nationally). In order to include 200 general practices, we randomly selected 12 -13 on each representative's list, with a further 1 or 2 as a backup to replace GPs who refused to participate. The GPs were therefore not selected on the basis of any specific characteristic that could have influenced the results.

Each consenting GP approached 50 consecutive patients aged 30 years or older to participate in the study. Patients were given an information sheet and written consent was obtained before including them in the study. Only demographic data were recorded for patients who refused consent. Management of patients with risk factors was left to the GPs’ discretion.

Risk-factor assessment and definitions

The GPs completed a 5-page questionnaire for each participating patient during the standard consultation for which the patient had attended the practice. The questionnaire included risk-factor and demographic information. The patient’s most recent blood pressure (BP) measurement was documented. We defined hypertension as past history of hypertension or a current presentation with a systolic BP ≥ 140 mmHg, or a diastolic BP of ≥ 90 mmHg. The highest result in the past 12 months for fasting total cholesterol, high-density lipoprotein (HDL), low-density lipoprotein (LDL), triglycerides and blood glucose were recorded if available. We defined dyslipidaemia as a past history of hypercholesterolaemia or a current presentation with a fasting cholesterol level > 5 mmol/l or LDL level > 3 mmol/l. DM was defined as a past history of DM or a current presentation with a fasting blood glucose level of ≥ 7 mmol/l. Current smoking status, a history of ever having smoked, alcohol use and a history of previous stroke or TIA were noted. A current presentation or history of atrial fibrillation were recorded. We defined atrial fibrillation as a past history of atrial fibrillation or a current presentation with atrial fibrillation or an irregular pulse rate. Current use of medication for cardiovascular risk factors was documented, as was a current presentation or past history of motor, sensory, speech, or cerebellar abnormalities, double vision, amaurosis fugax or dizziness.

Data analysis

Data were entered into EpilInfo and analysed using Stata 8. Descriptive statistics included the mean and standard deviations (SDs) as well as proportion with confidence intervals (CIs). We assessed the difference between population groups with regard to risk factors using chi-square tests. The distribution of the number of risk factors between the ethnic groups was compared using a Kruskal-Wallis test with adjustment after post hoc comparisons. We used logistical regression to determine the odds ratios (ORs) of the different population group categories for the various risk factors after adjusting for differences in age and gender.

Ethics

The Medicines Control Council confirmed that no formal approval was required other than ethics committee approval, as no drug was to be used in the study. Ethics committee approval was obtained from the University of Pretoria (120/2001) and Pharma-Ethics (ICE-9490 012-ZAF).

Results

Demographics

Two hundred general practices were registered after 79 of the randomised GPs who refused to participate had been replaced by others in the same geographical area, as close as possible to the original randomised practice. A total of 9 731 questionnaires were submitted questionnaires after the deadline date. The national distribution of participants was as follows (the percentage of the study sample and for comparison the percentage of the total South African population in the region are given in brackets for each region): Gauteng/Mpumalanga 2 689 participants (29%; 25%); Western Cape 1 744 participants (19%; 10%); KwaZulu-Natal 1 609 participants (18%,21%); Limpopo Province 1 506 participants (17%,12%); Central Provinces 855 participants (9%,17%); and Eastern Cape 544 participants (6%,16%). Although participating patients were widely distributed across South Africa, the majority were seen in metropolitan cities and rural areas were underrepresented.

Six per cent of participants (N = 618) were ineligible for analysis because of refusal (N = 303), missing most data (N = 187), or not meeting the inclusion criteria, e.g. under 30 years of age (N = 128). A total of 9 133 participants were therefore included and 303 non-participants excluded because of either patient refusal or doctor refusal to enter a particular individual. The mean age of participants was 50.7 years (SD 13.9, range 30-
100 years) and 73% of the participants were in the 30-59-year age range. The sex and population group distribution of participants and non-participants (because of refusal) was similar. Forty-five per cent of both the participants and non-participants were male, 23% of the participants were black, 7% coloured, 10% Asian, and 59% white; while 28% of the non-participants were black, 7% coloured, 8% Asian and 56% white.

Not all participants had all risk factors recorded. Only 31% had a total cholesterol reported and 40% had glucose values reported. In contrast, 96% of all participants had BP readings reported. Unfortunately, the proportion of tests done varied significantly among population groups. The proportion of each population group that had glucose values reported was as follows: black 30%, coloured 38%, Asian 55%, and white 41% (p < 0.001). The proportions for total cholesterol were: black 8%, coloured 22%, Asian 22% and white 43% (p < 0.001).

**Risk factors**

Seventy-six per cent of patients had 1 or more risk factors and 40% had 2 or more risk factors. There was a statistically significant difference (p < 0.001) in the number of risk factors between population groups. Post hoc testing showed that this distribution was significantly different between all groups except between the coloureds and Asians (p = 0.15, p < 0.004) required for significance). Of the 24% with no reported risk factors, the majority (32%) were black patients. Three or more risk factors occurred almost as commonly in the Asian, white and coloured groups (11-14%), but far less commonly in the black group (4%).

Table I shows the prevalence of risk factors by population group. Figs 1-3 graphically compare the prevalence of hypertension, dyslipidaemia, and a history of ever having smoked cigarettes by age group and population group. Hypertension is clearly the commonest risk factor in all population groups but stands out as the major risk factor in black patients. Logistical regression revealed that whites were 44% less likely to have hypertension than blacks even having adjusted for age and gender (OR 0.66, 95% CI: 0.59 - 0.74). The proportion of people still hypertensive despite treatment was 47%.

Whites were 10 times more likely to have dyslipidaemia than those blacks for whom information was available (OR 10.2, 95% CI: 8.3 - 12.5). As expected, DM was most common in the Asian population (26%) but surprisingly least common in the white population (8%). Most risk factors except cigarette smoking increased with age.

Atrial fibrillation was commonest in the white population (5%) followed by the coloured population (4%), and about equally common in the black and Asian population (2%). Current or past heart failure and venous thromboembolism were each present in 4% of participants. Ischaemic heart disease (past

---

**Table I. Risk-factor prevalence (percentage) by population group, adjusted for age and gender (95% confidence intervals)**

<table>
<thead>
<tr>
<th>Risk factor</th>
<th>Black</th>
<th>Coloured</th>
<th>Asian</th>
<th>White</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hypertension</td>
<td>59 (57 - 61)</td>
<td>55 (52 - 59)</td>
<td>55 (52 - 58)</td>
<td>50 (49 - 52)</td>
<td>55</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>14 (12 - 15)</td>
<td>15 (12 - 18)</td>
<td>26 (23 - 29)</td>
<td>8 (7 - 8)</td>
<td>16</td>
</tr>
<tr>
<td>Dyslipidaemia</td>
<td>5 (4 - 6)</td>
<td>23 (20 - 27)</td>
<td>22 (19 - 25)</td>
<td>37 (35 - 38)</td>
<td>22</td>
</tr>
<tr>
<td>History of ever smoking cigarettes</td>
<td>21 (20 - 23)</td>
<td>44 (40 - 48)</td>
<td>26 (24 - 29)</td>
<td>42 (41 - 44)</td>
<td>33</td>
</tr>
<tr>
<td>Atrial fibrillation</td>
<td>2 (2 - 3)</td>
<td>4 (2 - 6)</td>
<td>2 (1 - 3)</td>
<td>5 (5 - 6)</td>
<td>3</td>
</tr>
</tbody>
</table>

May 2005, Vol. 95, No. 5 SAMJ
Routine availability cotrimoxazole prophylaxis and occurrence of respiratory and diarrhoeal morbidity in infants born to HIV-infected mothers in South Africa

Anna Coutsoudis, Kubendran Pillay, Elizabeth Spooner, Hoosen M Coovadia, Lucy Pembrey, Marie-Louise Newell

Objectives. To examine the influence of cotrimoxazole (CTM) prophylaxis on incidence of lower respiratory tract infections (LRTIs) and diarrhoea.

Design. A prospective observational cohort study. Morbidity and feeding data on infants born to HIV-infected mothers were collected routinely at clinic visits at 1 week, 6 weeks and 3 months, and 3-monthly thereafter, with blood drawn for determining HIV status.

Setting. Two hospitals in Durban, South Africa. In one hospital (King Edward VIII Hospital), infants born to HIV-infected mothers who received CTM prophylaxis and in the other (McCord Hospital) infants did not receive CTM prophylaxis.

Subjects. Infants born to HIV-infected mothers.

Outcome measures. Incidence of LRTI and diarrhoea.

Results. In multivariate analysis controlling for breastfeeding status, number of clinic visits and HIV infection status, HIV-infected infants with access to CTM prophylaxis had a significantly lower incidence of LRTI (82%) than those without access to prophylaxis. However in HIV-uninfected infants, this was not the case. CTM prophylaxis was associated with a non-significant increased risk for diarrhoea in both infected (odds ratio (OR) 1.52, p = 0.10) and uninfected infants (OR 1.52, p = 0.10).

Conclusions. This observational study confirms current thinking that CTM prophylaxis is protective against LRTIs in HIV-infected children. However, because of a possible association between CTM prophylaxis and an increased risk of diarrhoea, HIV status of infants should be determined as early as possible in order to prevent unnecessary exposure of uninfected infants to CTM prophylaxis, while further studies to quantify both beneficial and adverse effects of CTM prophylaxis are undertaken.


Department of Paediatrics and Child Health, University of KwaZulu-Natal, Durban

Anna Coutsoudis, PhD
Kubendran Pillay, MB ChB
Elizabeth Spooner, MB ChB
Hoosen M Coovadia, MD

Centre for Paediatric Epidemiology and Biostatistics, Institute of Child Health, University College London, London, UK

Lucy Pembrey, MSc
Marie-Louise Newell, PhD

Corresponding author: A Coutsoudis (coutsoud@nu.ac.za)